BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Neurocampus - ECPv4.9.10//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bordeaux Neurocampus
X-ORIGINAL-URL:https://www.bordeaux-neurocampus.fr/en/
X-WR-CALDESC:Events for Bordeaux Neurocampus
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20210317T150000
DTEND;TZID=Europe/Paris:20210317T150000
DTSTAMP:20260529T171225
CREATED:20210129T140302Z
LAST-MODIFIED:20210203T140916Z
UID:130618-1615993200-1615993200@www.bordeaux-neurocampus.fr
SUMMARY:Thesis defense - William Fyke
DESCRIPTION:\n	\n		\n			Defense is held behind closed doors \n\n		\n	\n\n	\n		\n			Title: Identifying Therapeutic Targets for the Treatment of Fragile X Syndrome: Implications for Autism Spectrum Disorder \nThesis supervisors: Susanna Pietropaolo (INCIA) and Juan Marcos Alarcon (SUNY Downstate Medical Center\, Ney York) \n\nAbstract: Fragile X syndrome (FXS) is a neurodevelopmental disorder due to an X-linked mutation in the FMR1 gene that results in intellectual disability (ID)\, autism spectrum disorder (ASD)\, anxiety\, attention deficit hyperactivity disorder (ADHD) and sensory processing deficits. There is substantial overlap between FXS and ASD as approximately 30 to 50% of individuals diagnosed with FXS also meet the diagnostic criteria for ASD. Furthermore FXS-ASD patients represent approximately 5% of all cases of ASD. Since there is currently no targeted therapeutic approach\, novel pharmacological agents addressing the neurobiological underpinnings of these disorders are crucially needed. Due to the overlap between the two conditions\, systems which are disrupted in FXS and ASD patients may provide targets for treating the ASD symptoms observed in FXS-ASD patients and some non-syndromic ASD patients. FMRP\, the protein lost by the FMR1 mutation\, is a potent regulator of the endocannabinoid system (ECS) and BKCa channels. These function to regulate presynaptic excitability. Dysfunction in these systems is found in FXS patients and some ASD patients. The presynaptic role of these agents conceptualizes the “presynaptic hypothesis of FXS-ASD”. This project used genetic and pharmacological approaches which target FMRP\, the ECS or BKCa channels in combination with an extensive behavioral characterization of FXS and ASD-relevant phenotypes\, in order to assess the therapeutic value of these targets. This work demonstrates that the ECS and BKCa channels contribute to behavioral domains affected in neurodevelopmental disorders and offer several targets for therapeutics which should be explored. \n  \nKeywords: neurodevelopmental disorders\, animal models\, fragile x syndrome\, autism spectrum disorder \nAccepted Manuscripts\nFyke\, W.\, Alarcon\, J.M.\, Velinov\, M.\, & Chadman\, K.K. (2021) Pharmacological inhibition of BKCa channels induces a specific social deficit in adult C57BL6/J mice [Behavioral Neuroscience] \nManuscripts in review\nFyke\, W.\, Alarcon\, J.M.\, Velinov\, M.\, & Chadman\, K.K. (2021) Pharmacological inhibition of the primary endocannabinoid producing enzyme\, DGL-α\, induces ASD-like and co-morbid phenotypes in adult C57BL/J mice. [Autism Research] \nMendoza\, R*. Fyke\, W*.\, Daniel\, D.\, Gabutan\, E.\, Ballabh\, D.\, Easy\, M.\, Vasileva\, A.\, Colbourn\, R.\, Alawad\, M.\, Dehghani\, A.\, Lin\, B.\, Emechebe\, D.\, Patel\, P.\, Jabbar\, M.\, Nikolov\, D. B.\, Giovaniello\, D.\, Kang\, S.\, Tatem\, L.\, Bromberg\, K.\, Augenbraun\, M.\, Premsrirut\, P.\, Libien\, J.\, & Norin\, A.J. (2021) Administration of high titer convalescent anti-SARS-CoV-2 plasma: association with improved survival of hospitalized Covid-19 patients. [Human Immunology]  \n Mendoza\, R. Saha\, N. Momeni\, A. Gabutan\, E\, Alawad\, M. Dehghani\, A. Diks\, J. Lin\, B. Wang\, D. Alshal\, M.\, Fyke\, W.\, Alshal\, M.\, Wang\, B.\, Himanen\, J.\, Premsrirut\, P.\, & Nikolov\, D.B. (2021) Ephrin-A1 and the sheddase ADAM12 are upregulated in COVID-19 [Cell Reports]  \nManuscripts in preparation\nFyke\, W.\, Premoli\, M.\, Middei\, S.\, Lemaire-Mayo\, V.\, Wohr\, M.\, Crusio\, W.E.\, Marsicano\, G.\, & Pietropaolo\, S. (2021) Communication during post-natal development and adulthood in the CB1 mouse: Implications for Autism Spectrum Disorder. Target journal: Autism Research \nPremoli\, M*\, Fyke W*\, Lemaire-Mayo\, V.\, Belloochio\, L.\, Lecorf\, K.\, Wooley-Roberts\, M.\, Crusio\, W.E.\, & Pietropaolo\, S. (2020) Evaluation of the neurobehavioral effects of CBDV administration in the Fmr1-KO mouse model of Fragile X Syndrome: the relevance of early treatments. Target journal: Neuropsychopharmacology \nCrusio\, W. E. Lemaire-Mayo\, V. Fyke\, W. Premoli\, M.\, Subashi\, E.\, Delprato\, A.\, & Pietropaolo\, S. Effects of prenatal stress on the behavior of Fmr1 knock-out mice. Target journal: Behavioral Brain Research \n*Co-first author \n\n		\n	\n\n	\n		\n			 \nWilliam Fyke \nAffiliations : \nInstitut de Neurosciences Cognitives et Intégratives d’Aquitaine\,\nCNRS UMR 5287 \nSUNY Downstate Health Sciences Center\nSchool of Graduate Studies – Neural and Behavioral Science\n450 Clarkson Ave\nBrooklyn\, NY 11203 \n\n		\n	\n\n
URL:https://www.bordeaux-neurocampus.fr/en/event/thesis-defense-william-fyke/
CATEGORIES:Thesis
END:VEVENT
END:VCALENDAR